Rachna Khosla - May 2, 2022 Form 4 Insider Report for AMGEN INC (AMGN)

Role
SVP, Business Development
Signature
/s/ Rachna Khosla
Stock symbol
AMGN
Transactions as of
May 2, 2022
Transactions value $
-$12,239
Form type
4
Date filed
5/4/2022, 08:00 PM
Previous filing
Apr 29, 2022
Next filing
May 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Award $0 +606 +8.88% $0.00 7.43K May 2, 2022 Direct F1
transaction AMGN Common Stock Tax liability -$12.2K -53 -0.71% $230.92 7.38K May 3, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Award $0 +4.95K $0.00 4.95K May 2, 2022 Common Stock 4.95K $230.92 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.
F2 These shares include the following RSUs granted under the Company's equity plans: 554 RSUs which will vest on 7/31/2022; 142 RSUs which vest in one installment of 142 on 5/3/2023; 300 RSUs which will vest in two installments of 99 on 5/5/2022 and 5/5/2023 and one installment of 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3 These shares include 145 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4 These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.